Key Developments For Repros Therapeutics Inc.
Repros Therapeutics Inc. (RPRX.O) (Consolidated Issue listed on NASDAQ Global Market)
Repros Therapeutics Inc. Appoints Joseph S. Podolski As President-Form 8-K
Repros Therapeutics Inc. reported in its Form 8-K that on November 16, 2009, the Board elected Joseph S. Podolski as President of the Company.
Repros Therapeutics Inc. Announces Change Of Chairman
Repros Therapeutics Inc. announced that Nola E. Masterson, a Board member, has been appointed as Chairman of the Board of Directors, effective immediately, and that Mark Lappe, the current Chairman, has resigned from the Board, effective immediately, for personal reasons.
Repros Therapeutics Inc. Announces Resignation Of Paul Lammers As President-Form 8-K
Repros Therapeutics Inc. reported in its Form 8-K that as of October 29, 2009, Dr. Paul Lammers resigned his positions as the Company's President and Secretary to become the Chief Executive Officer of Mirna Therapeutics.
Repros Therapeutics Inc. Announces Financing
Repros Therapeutics Inc. announced that Repros has entered into a definitive agreement with institutional investors to sell 3.5 million shares of its common stock at $1.27 per share for gross proceeds of approximately $4.4 million. The offering is expected to close on or about October 9, 2009.
Repros Therapeutics Inc. Reports Androxal Restores Normal Sperm Counts While Increasing Testosterone Levels In Hypogonadal Men
Repros Therapeutics Inc. announced results from an exploratory, efficacy and safety study of its oral investigational product, enclomiphene citrate (Androxal), in men with secondary hypogonadism who were receiving testosterone replacement treatment. Secondary hypogonadism is a deficiency state in which the male hormone testosterone goes below the normal range, even in aging men, due to inadequate stimulation of the testes by the pituitary. The study was designed to compare Androxal to Testim1% (Auxilium Pharmaceuticals Inc, Malvern, PA), an approved topical testosterone gel, indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Group A vs. B: 7 men were randomized to Androxal and 5 men to Testim. After stopping their previous topical testosterone treatment for 3 weeks, the study subjects had baseline morning mean TT values of 165 ± 66 ng/dL, confirming their hypogonadal state. At 3 and 6 months of treatment, there was a statistically significant increase in mean TT compared with baseline in both treatment groups. TT was not significantly different between the 2 groups at 3 (p = 0.29) and 6 months (p = 0.90). At 6 months, mean TT levels were 545 ± 269 and 525 ± 256 ng/dL for the men receiving Testim and Androxal, respectively. These values are well within the normal range (300-1000 ng/dL).
